<DOC>
	<DOCNO>NCT01508000</DOCNO>
	<brief_summary>Patients present multiple innumerable liver metastases probably never come resection , however , others , include patient numerous multiple metastasis large metastasis , resection consider limited chemotherapy . There consensus backbone chemotherapy consist fluoropyrimidine + oxaliplatin . FOLFOX use previous EORTC study recommend . The addition target agent standard chemotherapy perioperative strategy mCRC might increase ORR R0 resectability , without significant increase toxicity , therefore translate well outcome . It therefore decide design open label , randomize , multi-center , 3-arm late phase II study . Arm A : ( standard ) mFOLFOX6 + Surgery Arm B : ( experimental ) mFOLFOX6 + Bevacizumab + Surgery Arm C : ( experimental ) mFOLFOX6 + Panitumumab + Surgery</brief_summary>
	<brief_title>Efficacy FOLFOX Alone , FOLFOX Plus Bevacizumab FOLFOX Plus Panitumumab Patients With Resectable Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven CRC 1 8 metachronous synchronous liver metastasis consider completely resectable . Primary tumor ( liver metastasis ) CRC must KRAS NRAS status `` wild type '' . Patients must undergo complete resection ( R0 ) primary tumor least 4 week randomization . Or patient synchronous metastasis primary tumor resect ( R0 ) time liver metastasis : patient nonobstructive primary tumor able receive preoperative chemotherapy ( 34 month ) surgery . Measurable hepatic disease RECIST version 1.1 . Patients must 18 year old old . A WHO performance status 0 1 . Radiotherapy alone allow give pre post protocol treatment . Previous adjuvant chemotherapy primary CRC allow complete least 12 month inclusion study . All following test do within 4 week prior randomization : Absolute neutrophil count ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 9 g/dL white blood cell count ( WBC ) ≥ 3 x 109/L . Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) ( exclude severe renal impairment ) ; significant proteinuria ( urine protein &lt; 1g/24 hour urine collection ) OR urine protein/creatinine ratio &lt; 1.0 OR 1+ proteinuria urine dipstick . Absence major hepatic insufficiency ( bilirubin ≤ 1.5 x ULN aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) ≤ 5 x ULN ) . Magnesium ≥ low limit normal ( LLN ) Patients buffer range normal value +/ 5 % hematology +/ 10 % biochemistry acceptable . This apply Renal Function , include Creatinine . Women child bear potential ( WOCBP ) must negative serum ( urine ) pregnancy test within 14 day prior first dose study treatment . Patients childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least 6 month last study treatment . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly . Female subject breast feed discontinue nursing prior first dose study treatment 6 month last study treatment . Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Evidence extrahepatic metastasis ( CRC ) . Previous chemotherapy metastatic disease surgical treatment ( e.g . surgical resection radiofrequency ablation ) liver metastasis . Previous exposure EGFR VEGF/VEGFR target therapy within last 12 month . Major surgical procedure , open biopsy , significant traumatic injury within 4 week prior randomization . Regular use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) . Bleeding diathesis ( e.g . hemoptysis ≥ 1/2 teaspoon 2.5mL ) , coagulopathy , need administration fulldose anticoagulant ( ) . Clinically significant cardiovascular disease , include : uncontrolled hypertension , New York Heart Association ( NYHA ) class IIIV heart failure , myocardial infarction unstable angina pectoris , cerebrovascular accident transient ischemic attack within past 12 month , peripheral vascular disease ≥ grade 2 , serious cardiac arrhythmia require medication clinically significant cardiovascular disease . Peripheral neuropathy &gt; grade 1 ( Common Terminology Criteria Adverse Events , v4.0 ) serious wound complication , ulcer , bone fracture . Symptomatic diverticulitis active uncontrolled gastroduodenal ulceration . History evidence interstitial lung disease ( e.g . pneumonitis , pulmonary fibrosis ) Significant disease , investigator 's opinion , would exclude patient study . Including know allergy adverse reaction study drug ( include excipients ) relate compound , include hypersensitivity Chinese hamster ovary ( CHO ) cell product recombinant human humanize antibody . Presence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . Participation another clinical study ( except sub study protocol ) within 30 day randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Liver metastasis</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>KRAS wild type</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Randomized</keyword>
	<keyword>Phase II</keyword>
	<keyword>Perioperative treatment</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Neo-adjuvant</keyword>
	<keyword>Surgery</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>